Liaoning Chengda BiotechnologyLtd Past Earnings Performance
Past criteria checks 1/6
Liaoning Chengda BiotechnologyLtd's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 1.6% per year. Liaoning Chengda BiotechnologyLtd's return on equity is 3.5%, and it has net margins of 19.3%.
Key information
-13.7%
Earnings growth rate
-16.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -1.6% |
| Return on equity | 3.5% |
| Net Margin | 19.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Liaoning Chengda BiotechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,718 | 332 | 639 | 288 |
| 30 Jun 24 | 1,759 | 353 | 675 | 278 |
| 31 Mar 24 | 1,761 | 420 | 677 | 235 |
| 31 Dec 23 | 1,750 | 466 | 658 | 220 |
| 30 Sep 23 | 1,789 | 588 | 653 | 188 |
| 30 Jun 23 | 1,805 | 667 | 623 | 187 |
| 31 Mar 23 | 1,802 | 690 | 607 | 208 |
| 31 Dec 22 | 1,815 | 714 | 601 | 211 |
| 30 Sep 22 | 1,713 | 653 | 641 | 228 |
| 30 Jun 22 | 1,797 | 698 | 610 | 240 |
| 31 Mar 22 | 1,859 | 763 | 611 | 220 |
| 31 Dec 21 | 2,088 | 892 | 620 | 237 |
| 30 Sep 21 | 2,069 | 916 | 557 | 233 |
| 30 Jun 21 | 2,138 | 970 | 561 | 221 |
| 31 Mar 21 | 2,091 | 942 | 537 | 229 |
| 31 Dec 20 | 1,996 | 918 | 501 | 222 |
| 30 Sep 20 | 2,058 | 919 | 515 | 237 |
| 30 Jun 20 | 1,970 | 899 | 492 | 215 |
| 31 Mar 20 | 1,895 | 817 | 507 | 184 |
| 31 Dec 19 | 1,677 | 698 | 490 | 153 |
| 30 Sep 19 | 1,532 | 713 | 447 | 91 |
| 30 Jun 19 | 1,461 | 650 | 447 | 77 |
| 31 Mar 19 | 1,425 | 650 | 424 | 80 |
| 01 Jan 19 | 1,391 | 627 | 409 | 68 |
| 30 Sep 18 | 1,418 | 612 | 446 | 73 |
| 30 Jun 18 | 1,357 | 593 | 410 | 73 |
| 31 Mar 18 | 1,308 | 579 | 362 | 67 |
| 31 Dec 17 | 1,276 | 556 | 367 | 52 |
| 30 Sep 17 | 1,278 | 577 | 315 | 34 |
| 30 Jun 17 | 1,146 | 482 | 301 | 22 |
| 31 Mar 17 | 1,011 | 429 | 297 | 0 |
| 31 Dec 16 | 1,030 | 457 | 289 | 0 |
| 30 Sep 16 | 925 | 410 | 295 | 0 |
| 30 Jun 16 | 904 | 447 | 275 | 0 |
| 31 Mar 16 | 924 | 452 | 277 | 0 |
| 31 Dec 15 | 943 | 458 | 279 | 0 |
| 30 Sep 15 | 964 | 475 | 280 | 0 |
| 30 Jun 15 | 978 | 478 | 272 | 0 |
| 31 Mar 15 | 957 | 460 | 269 | 0 |
| 31 Dec 14 | 937 | 442 | 276 | 0 |
| 31 Dec 13 | 851 | 404 | 257 | 0 |
Quality Earnings: 688739 has high quality earnings.
Growing Profit Margin: 688739's current net profit margins (19.3%) are lower than last year (32.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688739's earnings have declined by 13.7% per year over the past 5 years.
Accelerating Growth: 688739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688739 had negative earnings growth (-43.6%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Return on Equity
High ROE: 688739's Return on Equity (3.5%) is considered low.